Photodiagnosis and Photodynamic Therapy
Volume 2, Issue 4 , Pages 247-262 , December 2005

The potential for photodynamic therapy in the treatment of localized infections

References 

  1. Subramanian G, Mural R, Hoffman SL, Venter JC, Broder S. Microbial disease in humans: a genomic perspective. Mol Diagn. 2001;6:243–252
  2. Coates A, Hu Y, Bax R, Page C. The future challenges facing the development of new antimicrobial drugs. Nat Rev Drug Discov. 2002;1:895–910
  3. Orenstein A, Klein D, Kopolovic J, et al. The use of porphyrins for eradication of Staphylococcus aureus in burn wound infections. FEMS Immunol Med Microbiol. 1998;19:307–314
  4. Embleton ML, Nair SP, Cookson BD, Wilson M. Selective lethal photosensitization of methicillin-resistant Staphylococcus aureus using an IgG-Tin(IV) chlorin e6 conjugate. J Antimicrob Chemother. 2002;50:857–864
  5. Embleton ML, Nair SP, Cookson BD, Wilson M. Antibody-directed photodynamic therapy of methicillin resistant Staphylococcus aureus. Microb Drug Resist. 2004;10:92–97
  6. Griffiths MA, Wren BW, Wilson M. Killing of methicillin-resistant Staphylococcus aureus in vitro using aluminium disulphonated phthalocyanine, a light-activated antimicrobial agent. J Antimicrob Chemother. 1997;40:873–876
  7. Szpakowska M, Lasocki K, Grzybowski J, Graczyk A. Photodynamic activity of the haematoporphyrin derivative with rutin and arginine substituents (HpD-rut(2)-arg(2)) against Staphylococcus aureus and Pseudomonas aeruginosa. Pharmacol Res. 2001;44:243–246
  8. Hunt DW, Margaron P. Status of therapies in development for the treatment of age-related macular degeneration. IDrugs. 2003;6:464–469
  9. Raab O. Ueber die wirkung fluoreszierender stoffe auf infusoria. Z Biol. 1900;39:524–546
  10. Hamblin MR, Hasan T. Photodynamic therapy: a new antimicrobial approach to infectious disease?. Photochem Photobiol Sci. 2004;3:436–450
  11. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J Antimicrob Chemother. 1998;42:13–28
  12. Jori G, Brown SB. Photosensitized inactivation of microorganisms. Photochem Photobiol Sci. 2004;3:403–405
  13. Maisch T, Szeimies RM, Jori G, Abels C. Antibacterial photodynamic therapy in dermatology. Photochem Photobiol Sci. 2004;3:907–917
  14. Soukos NS, Wilson M, Burns T, Speight PM. Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro. Lasers Surg Med. 1996;18:253–259
  15. Lavi A, Weitman H, Holmes RT, Smith KM, Ehrenberg B. The depth of porphyrin in a membrane and the membrane's physical properties affect the photosensitizing efficiency. Biophys J. 2002;82:2101–2110
  16. Castano AP, Demidova TN, Hamblin MR. Mechanisms in photodynamic therapy: Part one—Photosensitizers, photochemistry and cellular localization. Photodiagn Photodynam Ther. 2004;1:279–293
  17. Salmon-Divon M, Nitzan Y, Malik Z. Mechanistic aspects of Escherichia coli photodynamic inactivation by cationic tetra-meso(N-methylpyridyl)porphine. Photochem Photobiol Sci. 2004;3:423–429
  18. Schafer M, Schmitz C, Facius R, et al. Systematic study of parameters influencing the action of rose bengal with visible light on bacterial cells: comparison between the biological effect and singlet-oxygen production. Photochem Photobiol. 2000;71:514–523
  19. Schafer M, Schmitz C, Horneck G. High sensitivity of Deinococcus radiodurans to photodynamically produced singlet oxygen. Int J Radiat Biol. 1998;74:249–253
  20. Bertoloni G, Lauro FM, Cortella G, Merchat M. Photosensitizing activity of hematoporphyrin on Staphylococcus aureus cells. Biochim Biophys Acta. 2000;1475:169–174
  21. Nitzan Y, Dror R, Ladan H, et al. Structure–activity relationship of porphines for photoinactivation of bacteria. Photochem Photobiol. 1995;62:342–347
  22. Minnock A, Vernon DI, Schofield J, et al. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both Gram-negative and Gram-positive bacteria. J Photochem Photobiol B. 1996;32:159–164
  23. Merchat M, Bertolini G, Giacomini P, Villanueva A, Jori G. Meso-substituted cationic porphyrins as efficient photosensitizers of Gram-positive and Gram-negative bacteria. J Photochem Photobiol B. 1996;32:153–157
  24. Merchat M, Spikes JD, Bertoloni G, Jori G. Studies on the mechanism of bacteria photosensitization by meso-substituted cationic porphyrins. J Photochem Photobiol B. 1996;35:149–157
  25. Hamblin MR, O’Donnell DA, Murthy N, et al. Polycationic photosensitizer conjugates: effects of chain length and Gram classification on the photodynamic inactivation of bacteria. J Antimicrob Chemother. 2002;49:941–951
  26. Hiramatsu K, Cui L, Kuwahara-Arai K. Has vancomycin-resistant Staphylococcus aureus started going it alone?. Lancet. 2004;364:565–566
  27. Wilson M, Yianni C. Killing of methicillin-resistant Staphylococcus aureus by low-power laser light. J Med Microbiol. 1995;42:62–66
  28. Usacheva MN, Teichert MC, Biel MA. Comparison of the methylene blue and toluidine blue photobactericidal efficacy against Gram-positive and Gram-negative microorganisms. Lasers Surg Med. 2001;29:165–173
  29. Usacheva MN, Teichert MC, Biel MA. The role of the methylene blue and toluidine blue monomers and dimers in the photoinactivation of bacteria. J Photochem Photobiol B. 2003;71:87–98
  30. Wainwright M, Phoenix DA, Laycock SL, Wareing DR, Wright PA. Photobactericidal activity of phenothiazinium dyes against methicillin-resistant strains of Staphylococcus aureus. FEMS Microbiol Lett. 1998;160:177–181
  31. Wainwright M, Phoenix DA, Gaskell M, Marshall B. Photobactericidal activity of methylene blue derivatives against vancomycin-resistant Enterococcus spp. J Antimicrob Chemother. 1999;44:823–824825
  32. O’Neill J, Wilson M, Wainwright M. Comparative antistreptococcal activity of photobactericidal agents. J Chemother. 2003;15:329–334
  33. Phoenix DA, Sayed Z, Hussain S, Harris F, Wainwright M. The phototoxicity of phenothiazinium derivatives against Escherichia coli and Staphylococcus aureus. FEMS Immunol Med Microbiol. 2003;39:17–22
  34. Kubin A, Wierrani F, Jindra RH, et al. Antagonistic effects of combination photosensitization by hypericin, meso-tetrahydroxyphenylchlorin (mTHPC) and photofrin II on Staphylococcus aureus. Drugs Exp Clin Res. 1999;25:13–21
  35. Wierrani F. Experimental investigations and clinical use of photodynamic therapy (PDT) in the rudolf foundation hospital. Gynakol Geburtshilfliche Rundsch. 1999;39:217–225
  36. Segalla A, Borsarelli CD, Braslavsky SE, et al. Photophysical, photochemical and antibacterial photosensitizing properties of a novel octacationic Zn(II)-phthalocyanine. Photochem Photobiol Sci. 2002;1:641–648
  37. Lasocki K, Szpakowska M, Grzybowski J, Graczyk A. Examination of antibacterial activity of the photoactivated arginine haematoporphyrin derivative. Pharmacol Res. 1999;39:181–184
  38. Nitzan Y, Salmon-Divon M, Shporen E, Malik Z. ALA induced photodynamic effects on Gram positive and negative bacteria. Photochem Photobiol Sci. 2004;3:430–435
  39. Gross S, Brandis A, Chen L, et al. Protein-A-mediated targeting of bacteriochlorophyll-IgG to Staphylococcus aureus: a model for enhanced site-specific photocytotoxicity. Photochem Photobiol. 1997;66:872–878
  40. Gad F, Zahra T, Hasan T, Hamblin MR. Effects of growth phase and extracellular slime on photodynamic inactivation of Gram-positive pathogenic bacteria. Antimicrob Agents Chemother. 2004;48:2173–2178
  41. Ashkenazi H, Malik Z, Harth Y, Nitzan Y. Eradication of Propionibacterium acnes by its endogenic porphyrins after illumination with high intensity blue light. FEMS Immunol Med Microbiol. 2003;35:17–24
  42. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy of acne vulgaris with topical delta-aminolaevulinic acid and incoherent light in Japanese patients. Br J Dermatol. 2001;144:575–579
  43. Itoh Y, Ninomiya Y, Tajima S, Ishibashi A. Photodynamic therapy for acne vulgaris with topical 5-aminolevulinic acid. Arch Dermatol. 2000;136:1093–1095
  44. Pollock B, Turner D, Stringer MR, et al. Topical aminolevulinic acid-photodynamic therapy for the treatment of acne vulgaris: a study of clinical efficacy and mechanism of action. Br J Dermatol. 2004;151:616–622
  45. Rudolph RI. Some articles should just not be published. Arch Dermatol. 2001;137:964–965
  46. Romanova NA, Brovko LY, Moore L, et al. Assessment of photodynamic destruction of Escherichia coli O157:H7 and Listeria monocytogenes by using ATP bioluminescence. Appl Environ Microbiol. 2003;69:6393–6398
  47. Wilson M. Lethal photosensitisation of oral bacteria and its potential application in the photodynamic therapy of oral infections. Photochem Photobiol Sci. 2004;3:412–418
  48. Wood S, Nattress B, Kirkham J, et al. An in vitro study of the use of photodynamic therapy for the treatment of natural oral plaque biofilms formed in vivo. J Photochem Photobiol B. 1999;50:1–7
  49. Burns T, Wilson M, Pearson GJ. Effect of dentine and collagen on the lethal photosensitization of Streptococcus mutans. Caries Res. 1995;29:192–197
  50. van der Meulen FW, Ibrahim K, Sterenborg HJ, et al. Photodynamic destruction of Haemophilus parainfluenzae by endogenously produced porphyrins. J Photochem Photobiol B. 1997;40:204–208
  51. Henry CA, Dyer B, Wagner M, Judy M, Matthews JL. Phototoxicity of argon laser irradiation on biofilms of Porphyromonas and Prevotella species. J Photochem Photobiol B. 1996;34:123–128
  52. Henry CA, Judy M, Dyer B, Wagner M, Matthews JL. Sensitivity of Porphyromonas and Prevotella species in liquid media to argon laser. Photochem Photobiol. 1995;61:410–413
  53. Matevski D, Weersink R, Tenenbaum HC, et al. Lethal photosensitization of periodontal pathogens by a red-filtered xenon lamp in vitro. J Periodontal Res. 2003;38:428–435
  54. Millson CE, Wilson M, MacRobert AJ, Bown SG. Ex-vivo treatment of gastric Helicobacter infection by photodynamic therapy. J Photochem Photobiol B. 1996;32:59–65
  55. Ashkenazi H, Nitzan Y, Gal D. Photodynamic effects of antioxidant substituted porphyrin photosensitizers on Gram-positive and -negative bacterial. Photochem Photobiol. 2003;77:186–191
  56. Usacheva MN, Teichert MC, Biel MA. The interaction of lipopolysaccharides with phenothiazine dyes. Lasers Surg Med. 2003;33:311–319
  57. Komerik N, Wilson M, Poole S. The effect of photodynamic action on two virulence factors of Gram-negative bacteria. Photochem Photobiol. 2000;72:676–680
  58. Moller KI, Kongshoj B, Philipsen PA, Thomsen VO, Wulf HC. How Finsen's light cured lupus vulgaris. Photodermatol Photoimmunol Photomed. 2005;21:118–124
  59. Sharlin D, Gross J, Nau G, Hasan T. Photodynamic destruction of mycobacteria in a new animal model for localized infection. Abstract from the Proceedings of the 30th Annual Meeting of the American Society for Photobiology; 2002.
  60. Hamblin MR, O’Donnell DA, Murthy N, Contag CH, Hasan T. Rapid control of wound infections by targeted photodynamic therapy monitored by in vivo bioluminescence imaging. Photochem Photobiol. 2002;75:51–57
  61. Hamblin MR, Zahra T, Contag CH, McManus AT, Hasan T. Optical monitoring and treatment of potentially lethal wound infections in vivo. J Infect Dis. 2003;187:1717–1725
  62. Gad F, Zahra T, Francis KP, Hasan T, Hamblin MR. Targeted photodynamic therapy of established soft-tissue infections in mice. Photochem Photobiol Sci. 2004;3:451–458
  63. Berthiaume F, Reiken SR, Toner M, Tompkins RG, Yarmush ML. Antibody-targeted photolysis of bacteria in vivo. Biotechnology. 1994;12:703–706
  64. Komerik N, Nakanishi H, MacRobert AJ, et al. In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model. Antimicrob Agents Chemother. 2003;47:932–940
  65. Hepburn NC. Cutaneous leishmaniasis: current and future management. Expert Rev Anti Infect Ther. 2003;1:563–570
  66. Gardlo K, Hanneken S, Ruzicka T, Neumann NJ. Photodynamic therapy of cutaneous leishmaniasis. A promising new therapeutic modality. Hautarzt. 2004;55:381–383
  67. Gardlo K, Horska Z, Enk CD, et al. Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol. 2003;48:893–896
  68. Enk CD, Gardlo K, Hochberg M, Ingber A, Ruzicka T. Cutaneous leishmaniasis. Hautarzt. 2003;54:506–512
  69. Sah JF, Ito H, Kolli BK, Peterson DA, Sassa S, Chang KP. Genetic rescue of leishmania deficiency in porphyrin biosynthesis creates mutants suitable for analysis of cellular events in uroporphyria and for photodynamic therapy. J Biol Chem. 2002;277:14902–14909
  70. El-On J, Katz M, Weinrauch L. Treatment of cutaneous leishmaniasis by photodynamic therapy. J Am Acad Dermatol. 2004;50:e12;[author reply e13]
  71. Gottlieb P, Shen LG, Chimezie E, et al. Inactivation of Trypanosoma cruzi trypomastigote forms in blood components by photodynamic treatment with phthalocyanines. Photochem Photobiol. 1995;62:869–874
  72. Lo PC, Huang JD, Cheng DY, et al. New amphiphilic silicon(IV) phthalocyanines as efficient photosensitizers for photodynamic therapy: synthesis, photophysical properties, and in vitro photodynamic activities. Chemistry. 2004;10:4831–4838
  73. Kassab K, Dei D, Roncucci G, Jori G, Coppellotti O. Phthalocyanine-photosensitized inactivation of a pathogenic protozoan, Acanthamoeba palestinensis. Photochem Photobiol Sci. 2003;2:668–672
  74. Ishii K, Takeuchi S, Shimizu S, Kobayashi N. A concept for controlling singlet oxygen (1 delta g) yields using nitroxide radicals: phthalocyaninatosilicon covalently linked to nitroxide radicals. J Am Chem Soc. 2004;126:2082–2088
  75. Kudrik EV, Makarov SV, Zahi A, van Eldik R. Kinetics and mechanism of the cobalt phthalocyanine catalyzed reduction of nitrite and nitrate by dithionite in aqueous solution. Inorg Chem. 2003;42:618–624
  76. Linares E, Giorgio S, Mortara RA, Santos CX, Yamada AT, Augusto O. Role of peroxynitrite in macrophage microbicidal mechanisms in vivo revealed by protein nitration and hydroxylation. Free Radic Biol Med. 2001;30:1234–1242
  77. Brandonisio O, Panaro MA, Sisto M, et al. Nitric oxide production by leishmania-infected macrophages and modulation by cytokines and prostaglandins. Parassitologia. 2001;43:1–6
  78. Abok K, Cadenas E, Brunk U. An experimental model system for leishmaniasis. Effects of porphyrin-compounds and menadione on leishmania parasites engulfed by cultured macrophages. APMIS. 1988;96:543–551
  79. Zijlstra EE, Musa AM, Khalil EA, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Infect Dis. 2003;3:87–98
  80. Evans S, Matthews W, Perry R, et al. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst. 1990;82:34–39
  81. Gollnick SO, Evans SS, Baumann H, et al. Role of cytokines in photodynamic therapy-induced local and systemic inflammation. Br J Cancer. 2003;88:1772–1779
  82. Yamamoto N, Homma S, Sery TW, Donoso LA, Hoober JK. Photodynamic immunopotentiation: in vitro activation of macrophages by treatment of mouse peritoneal cells with haematoporphyrin derivative and light. Eur J Cancer. 1991;27:467–471
  83. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis. J Antimicrob Chemother. 1995;35:103–114
  84. Teichert MC, Jones JW, Usacheva MN, Biel MA. Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:155–160
  85. Bertoloni G, Reddi E, Gatta M, Burlini C, Jori G. Factors influencing the haematoporphyrin-sensitized photoinactivation of Candida albicans. J Gen Microbiol. 1989;135:957–966
  86. Stenstrom AG, Moan J, Brunborg G, Eklund T. Photodynamic inactivation of yeast cells sensitized by hematoporphyrin. Photochem Photobiol. 1980;32:349–352
  87. Smijs TG, Schuitmaker HJ. Photodynamic inactivation of the dermatophyte Trichophyton rubrum. Photochem Photobiol. 2003;77:556–560
  88. Bliss JM, Bigelow CE, Foster TH, Haidaris CG. Susceptibility of candida species to photodynamic effects of photofrin. Antimicrob Agents Chemother. 2004;48:2000–2006
  89. Strakhovskaya MG, Ivanova EV, Kolesnikova OA, Fraikin GY. Effect of 2,2′-dipyridyl on accumulation of protoporphyrin IX and its derivatives in yeast mitochondria and plasma membranes. Biochemistry. 1999;64:213–216
  90. Strakhovskaya MG, Shumarina AO, Fraikin GY, Rubin AB. Endogenous porphyrin accumulation and photosensitization in the yeast Saccharomyces cerevisiae in the presence of 2,2′-dipyridyl. J Photochem Photobiol B. 1999;49:18–22
  91. Paardekooper M, Van Gompel AE, Van Steveninck J, Van den Broek PJ. The effect of photodynamic treatment of yeast with the sensitizer chloroaluminum phthalocyanine on various cellular parameters. Photochem Photobiol. 1995;62:561–567
  92. Kamp H, Tietz HJ, Lutz M, et al. Antifungal effect of 5-aminolevulinic acid PDT in Ttrichophyton rubrum. Mycoses. 2005;48:101–107
  93. Carre V, Gaud O, Sylvain I, et al. Fungicidal properties of meso-arylglycosylporphyrins: influence of sugar substituents on photoinduced damage in the yeast Saccharomyces cerevisiae. J Photochem Photobiol B. 1999;48:57–62
  94. Donnelly RF, McCarron PA, Lightowler JM, Woolfson AD. Bioadhesive patch-based delivery of 5-aminolevulinic acid to the nail for photodynamic therapy of onychomycosis. J Controlled Release. 2005;103:381–392
  95. Calzavara-Pinton PG, Venturini M, Capezzera R, Sala R, Zane C. Photodynamic therapy of interdigital mycoses of the feet with topical application of 5-aminolevulinic acid. Photodermatol Photoimmunol Photomed. 2004;20:144–147
  96. Bissonnette R, Sharfaei S, Viau G, Liu Y. Irradiance and light dose influence histological localization of photodamage induced by photodynamic therapy with aminolevulinic acid. Br J Dermatol. 2004;151:653–655
  97. Kaufman RH, Adam E, Mirkovic RR, Melnick JL, Young RL. Treatment of genital herpes simplex virus infection with photodynamic inactivation. Am J Obstet Gynecol. 1978;132:861–869
  98. Muller-Breitkreutz K, Mohr H. Infection cycle of herpes viruses after photodynamic treatment with methylene blue and light. Beitr Infusionsther Transfusionsmed. 1997;34:37–42
  99. Smetana Z, Ben-Hur E, Mendelson E, et al. Herpes simplex virus proteins are damaged following photodynamic inactivation with phthalocyanines. J Photochem Photobiol B. 1998;44:77–83
  100. Shikowitz MJ, Abramson AL, Steinberg BM, et al. Clinical trial of photodynamic therapy with meso-tetra (hydroxyphenyl) chlorin for respiratory papillomatosis. Arch Otolaryngol Head Neck Surg. 2005;131:99–105
  101. Uhlir M, Jirsa M, Otcenasek M, Halaska M, Feyereisl J. Photodynamic therapy of benign viral vulvar lesions. Ceska Gynekol. 2002;67:320–323
  102. Stender IM, Lock-Andersen J, Wulf HC. Recalcitrant hand and foot warts successfully treated with photodynamic therapy with topical 5-aminolaevulinic acid: a pilot study. Clin Exp Dermatol. 1999;24:154–159
  103. Stender IM, Na R, Fogh H, Gluud C, Wulf HC. Photodynamic therapy with 5-aminolaevulinic acid or placebo for recalcitrant foot and hand warts: randomised double-blind trial. Lancet. 2000;355:963–966
  104. Stender IM, Wulf HC. Photodynamic therapy of recalcitrant warts with 5-aminolevulinic acid: a retrospective analysis. Acta Derm Venereol. 1999;79:400–401
  105. Stender IM, Wulf HC. Treatment of recalcitrant verrucae by photodynamic therapy with topical application of delta-aminolevulinic acid. Clin Exp Dermatol. 1996;21:390
  106. Smetana Z, Malik Z, Orenstein A, Mendelson E, Ben-Hur E. Treatment of viral infections with 5-aminolevulinic acid and light. Lasers Surg Med. 1997;21:351–358
  107. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B. 1990;6:143–148
  108. Ammann R, Hunziker T, Braathen LR. Topical photodynamic therapy in verrucae. A pilot study. Dermatology. 1995;191:346–347
  109. Szeimies RM, Landthaler M, Karrer S. Non-oncologic indications for ALA-PDT. J Dermatolog Treat. 2002;13:S13–S18
  110. Wolfsen HC, Ng CS. Cutaneous consequences of photodynamic therapy. Cutis. 2002;69:140–142
  111. Ben-Hur E, Barshtein G, Chen S, Yedgar S. Photodynamic treatment of red blood cell concentrates for virus inactivation enhances red blood cell aggregation: protection with antioxidants. Photochem Photobiol. 1997;66:509–512
  112. Ben-Hur E, Oetjen J, Horowitz B. Silicon phthalocyanine pc 4 and red light causes apoptosis in HIV-infected cells. Photochem Photobiol. 1997;65:456–460
  113. Muller-Breitkreutz K, Mohr H. Hepatitis C and human immunodeficiency virus RNA degradation by methylene blue/light treatment of human plasma. J Med Virol. 1998;56:239–245
  114. Demidova TN, Hamblin MR. Effect of cell-photosensitizer binding and cell density on microbial photoinactivation. Antimicrob Agents Chemother. 2005;49:2329–2335
  115. Lee JC. The Staphylococcus aureus capsular polysaccharide and T cells influence the host–pathogen interaction in a wound infection model. Int Symp Staphylococcus Staphylococcal Infect 2002;266:01 [abstract ].
  116. Kobayashi W, Liu Q, Matsumiya T, et al. Photodynamic therapy upregulates expression of mac-1 and generation of leukotriene B(4) by human polymorphonuclear leukocytes. Oral Oncol. 2004;40(5):506–510
  117. Demidova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol. 2004;17:117–126

PII: S1572-1000(05)00099-2

doi: 10.1016/S1572-1000(05)00099-2

Photodiagnosis and Photodynamic Therapy
Volume 2, Issue 4 , Pages 247-262 , December 2005

Article Tools

* Image Usage & Resolution